Volume | 2,679 |
|
|||||
News | - | ||||||
Day High | 128.14 | Low High |
|||||
Day Low | 126.50 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Novo Nordisk (PK) | NONOF | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
126.50 | 126.50 | 128.14 | 124.25 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
12 | 2,679 | $ 127.5466 | $ 341,697 | - | 74.70 - 140.32 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:24:24 | 4 | $ 128.14 | USD |
Novo Nordisk (PK) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
570.99B | 2.30B | - | 232.26B | 83.68B | 18.61 | 6.82 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Novo Nordisk (PK) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NONOF Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 131.25 | 131.25 | 119.648 | 123.79 | 15,325 | -3.11 | -2.37% |
1 Month | 124.96 | 131.40 | 117.90 | 126.10 | 13,282 | 3.18 | 2.54% |
3 Months | 121.40 | 140.32 | 117.90 | 124.79 | 29,077 | 6.74 | 5.55% |
6 Months | 101.3125 | 140.32 | 94.36 | 115.81 | 32,664 | 26.83 | 26.48% |
1 Year | 85.50 | 140.32 | 74.70 | 104.54 | 28,302 | 42.64 | 49.87% |
3 Years | 38.695 | 140.32 | 36.025 | 76.78 | 22,335 | 89.45 | 231.15% |
5 Years | 24.195 | 140.32 | 23.145 | 58.33 | 22,219 | 103.95 | 429.61% |
Novo Nordisk (PK) Description
Novo-Nordisk is the parent company of a group engaged in the development, production and marketing of pharmaceuticals, biological solutions to industrial problems; vitamins, dietary supplements and digestive aids. Co. operates on a worldwide basis in two business segments: Diabetes care: discovery, development, manufacturing and marketing of products within the areas of insulin and delivery systems and oral antidiabetic products (OAD). Biopharmaceuticals: discovery, development, manufacturing and marketing of products within the therapy areas haemostasis management (NovoSeven(R) RT), growth hormone therapy, hormone replacement therapy and other products. |